StreetInsider.com News Articles

TD Cowen Downgrades EyePoint Inc. (EYPT) to Hold

Wed, 02 Sep 2026 02:04:30 -0400

TD Cowen analyst Tara Bancroft downgraded EyePoint Inc. (NASDAQ: EYPT) from Buy to Hold with a price target of $4.00 (from $20.00).

The analyst comments: “Following the failure of EyePoint's first Phase III wAMD study (note here), we found the LUGANO post-hoc analysis instructive and are sympathetic that the nine patients could represent an anomalous randomization scenario that disproportionately affected the Duravyu arm. Conversely, we realize that the chance of this occurring is rare and expect pervasive skepticism from both investors and regulators as a result.

Even so, the post-hoc analysis resulted in a -2.4 letter difference with a CI lower bound

TD Cowen Downgrades EyePoint Inc. (EYPT) to Hold

Wed, 02 Sep 2026 02:04:30 -0400

TD Cowen analyst Tara Bancroft downgraded EyePoint Inc. (NASDAQ: EYPT) from Buy to Hold with a price target of $4.00 (from $20.00).

Even so, the post-hoc analysis resulted in a -2.4 letter difference with a CI lower bound

Form 4 EyePoint, Inc. For: Aug 20 Filed by: Elston George

Mon, 24 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260824/26968198.html

Form 4 EyePoint, Inc. For: Aug 20 Filed by: Elston George

Mon, 24 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260824/26968198.html

Form 4 EyePoint, Inc. For: Aug 18 Filed by: Zaderej Karen L.

Tue, 18 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260818/26944260.html

Form 4 EyePoint, Inc. For: Aug 18 Filed by: Zaderej Karen L.

Tue, 18 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260818/26944260.html

EyePoint Pharmaceuticals (EYPT) call put ratio 1.4 calls to 1 put as share price up 8.9%

Tue, 18 Aug 2026 13:27:13 -0400

EyePoint Pharmaceuticals (NASDAQ: EYPT) 30-day option implied volatility is at 108; compared to its 52-week of 59 to 357. Call put ratio 1.4 calls to 1 put as share price up 8.9%.

Chardan Downgrades EyePoint Inc. (EYPT) to Neutral

Tue, 18 Aug 2026 08:11:17 -0400

Chardan analyst Andreas Argyrides downgraded EyePoint Inc. (NASDAQ: EYPT) from Buy to Neutral with a price target of $5.00 (from $65.00).

The analyst comments "With regulatory uncertainty now substantially higher heading into LUCIA, we reduce our estimated probability of approval to 10% from 60%. Accordingly, we lower our price target to $5 from $65 and move to the sidelines for now. While we acknowledge precedent for FDA approval based on one successful and one failed Phase 3 study, as highlighted by management through the examples of Apellis and Outlook, we believe those comparisons are imperfect. In our view, the key determinants

Chardan Downgrades EyePoint Inc. (EYPT) to Neutral

Tue, 18 Aug 2026 08:11:17 -0400

Chardan analyst Andreas Argyrides downgraded EyePoint Inc. (NASDAQ: EYPT) from Buy to Neutral with a price target of $5.00 (from $65.00).

H.C. Wainwright Downgrades EyePoint Inc. (EYPT) to Neutral

Tue, 18 Aug 2026 06:09:23 -0400

H.C. Wainwright analyst Yi Chen downgraded EyePoint Inc. (NASDAQ: EYPT) from Buy to Neutral.

For an analyst ratings summary and ratings history on EyePoint Inc. click here. For more ratings news on EyePoint Inc. click here.

Shares of EyePoint Inc. closed at $4.87 yesterday.

RBC Capital Downgrades EyePoint Inc. (EYPT) to Sector Perform

Tue, 18 Aug 2026 02:52:17 -0400

RBC Capital analyst Lisa Walter downgraded EyePoint Inc. (NASDAQ: EYPT) from Outperform to Sector Perform with a price target of $5.00 (from $37.00).

The analyst comments: “LUGANO missed its primary non-inferiority endpoint in the ITT population, and we view the data as a negative for EYPT shares. We are downgrading the stock to Sector Perform, Spec. Risk (from Outperform, Spec. Risk), as we think it will take time to clear the clinical and regulatory overhang created from the LUGANO study. Even if the second pivotal LUCIA has positive results, questions will remain whether DURAVYU is having a negative impact on vision

RBC Capital Downgrades EyePoint Inc. (EYPT) to Sector Perform

Tue, 18 Aug 2026 02:52:17 -0400

RBC Capital analyst Lisa Walter downgraded EyePoint Inc. (NASDAQ: EYPT) from Outperform to Sector Perform with a price target of $5.00 (from $37.00).

EyePoint Inc. (EYPT) PT Lowered to $48 at Laidlaw

Mon, 17 Aug 2026 15:24:23 -0400

Laidlaw analyst Yale Jen lowered the price target on EyePoint Inc. (NASDAQ: EYPT) to $48.00 (from $50.00) while maintaining a Buy rating.

Guggenheim Reiterates Buy Rating on EyePoint Inc. (EYPT)

Mon, 17 Aug 2026 13:01:42 -0400

Guggenheim analyst Yatin Suneja reiterated a Buy rating and $68.00 price target on EyePoint Inc. (NASDAQ: EYPT)

The analyst comments "This morning, EYPT announced topline results from LUGANO, the first of two pivotal Phase III wet AMD trials for Duravyu. While the primary endpoint of BCVA change vs. on-label aflibercept was not met in the full dataset, the miss was confounded by a 4% asymmetric cohort (9 of 211 Duravyu patients) who experienced ≥15-letter vision loss unrelated to wet AMD, with zero comparable events in the aflibercept control arm (vs. 3-5% historically in comparable trials). An ad hoc analysis excluding this

JPMorgan Downgrades EyePoint Inc. (EYPT) to Neutral

Mon, 17 Aug 2026 12:51:10 -0400

JPMorgan analyst Tessa Romero downgraded EyePoint Inc. (NASDAQ: EYPT) from Overweight to Neutral.

For an analyst ratings summary and ratings history on EyePoint Inc. click here. For more ratings news on EyePoint Inc. click here.

Shares of EyePoint Inc. closed at $14.75 yesterday.

EyePoint Inc. (EYPT) PT Lowered to $8 at Jefferies

Mon, 17 Aug 2026 12:31:01 -0400

Jefferies analyst Kambiz Yazdi lowered the price target on EyePoint Inc. (NASDAQ: EYPT) to $8.00 (from $30.00) while maintaining a Buy rating.

The analyst comments "Technically we're halfway there, but we're living on a prayer after a surprising mixed outcome in LUGANO. Primary ep was missed but driven by an "asymmetric" grp of 9pts in the DURAVYU arm with vision loss from non-wAMD causes. Without these 9pts, the study would have been positive. For what it's worth, injection burden reduction looked good. This is an unpredicted outcome and a lot now rides on a clean LUCIA readout in 2mos + regulatory

EyePoint Inc. (EYPT) PT Lowered to $8 at Jefferies

Mon, 17 Aug 2026 12:31:01 -0400

Jefferies analyst Kambiz Yazdi lowered the price target on EyePoint Inc. (NASDAQ: EYPT) to $8.00 (from $30.00) while maintaining a Buy rating.

Stifel on EyePoint Inc. (EYPT): 'we think these data bode well for LUCIA (expected October) barring another unusual asymmetry'

Mon, 17 Aug 2026 12:07:04 -0400

Stifel analyst Annabel Samimy reiterated a Buy rating and $40.00 price target on EyePoint Inc. (NASDAQ: EYPT).

The analyst comments "We reiterate our Buy rating on EYPT, $40 TP. While shares are heavily under pressure today, we are very impressed with the totality of the data generated from Ph.3 LUGANO despite the unfortunate miss in the primary endpoint from a patient imbalance that handicapped the treatment arm. Excluding an asymmetrical cohort of patients (9/211) that had ≥15 letters of BCVA loss UNRELATED to wAMD (vs. 0/216 for Eylea arm), non-inferiority was not only achieved with 2.4-letter variance (within 4.5-letter margin) but

Cantor Fitzgerald Downgrades EyePoint Inc. (EYPT) to Neutral

Mon, 17 Aug 2026 09:30:40 -0400

Cantor Fitzgerald analyst Steve Seedhouse downgraded EyePoint Inc. (NASDAQ: EYPT) from Overweight to Neutral.

For an analyst ratings summary and ratings history on EyePoint Inc. click here. For more ratings news on EyePoint Inc. click here.

Shares of EyePoint Inc. closed at $14.75 yesterday.

Form 8-K EyePoint, Inc. For: Aug 17

Mon, 17 Aug 2026 08:51:00 -0400

si-local-file:///var/storage/secattach/20260817/26935501.html

Form 8-K EyePoint, Inc. For: Aug 17

Mon, 17 Aug 2026 08:51:00 -0400

si-local-file:///var/storage/secattach/20260817/26935501.html

Citi cuts EyePoint price target to $17 from $35, keeps Buy, stock down 67%

Mon, 17 Aug 2026 08:41:24 -0400

Citi analyst Yigal Nochomovitz lowered his price target on EyePoint Pharmaceuticals (NASDAQ: EYPT) to $17.00 from $35.00, while maintaining a Buy rating on the stock.

The revision follows disappointing headline results from the LUGANO trial, which the analyst said raised risks for the related LUCIA trial. Nochomovitz reduced his probability of success estimate for wet age-related macular degeneration, known as wAMD, to 40% from 60%, and raised his weighted average cost of capital assumption to 15% from 13.5%.

The analyst noted several factors that he said could partially offset the increased risk. Only 0.5% of patients in the aflibercept-2mg arm of the

EyePoint's DURAVYU misses primary endpoint in wet AMD trial

Mon, 17 Aug 2026 07:01:09 -0400

EyePoint, Inc. (NASDAQ: EYPT) announced topline results from LUGANO, the first of two pivotal Phase 3 clinical trials evaluating DURAVYU (vorolanib intravitreal insert) for wet age-related macular degeneration (wet AMD).

The trial did not achieve its primary endpoint of non-inferiority in best corrected visual acuity (BCVA) change from baseline versus 2 mg aflibercept in the full dataset. The company attributed the result to a 4% asymmetric cohort — nine of 211 patients — who experienced vision loss of 15 or more letters unrelated to wet AMD. No patients in the aflibercept control arm experienced similar vision loss. In an ad hoc

EyePoint's DURAVYU misses primary endpoint in wet AMD trial

Mon, 17 Aug 2026 07:01:09 -0400

EyePoint's DURAVYU misses primary endpoint in wet AMD trial

Mon, 17 Aug 2026 07:01:09 -0400